Universe Pharmaceuticals INC
UPC
$4.91
-$0.21-4.10%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.07M | 5.07M | 6.44M | 6.44M | 6.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.07M | 5.07M | 6.44M | 6.44M | 6.92M |
| Cost of Revenue | 3.72M | 3.72M | 4.76M | 4.76M | 4.83M |
| Gross Profit | 1.35M | 1.35M | 1.68M | 1.68M | 2.09M |
| SG&A Expenses | 3.01M | 3.01M | 2.52M | 2.52M | 2.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 6.40K | 6.40K | -5.70K | -5.70K | 23.80K |
| Total Operating Expenses | 8.21M | 8.21M | 7.31M | 7.31M | 8.98M |
| Operating Income | -3.14M | -3.14M | -870.10K | -870.10K | -2.06M |
| Income Before Tax | 2.16M | 2.16M | -6.22M | -6.22M | -2.29M |
| Income Tax Expenses | -29.20K | -29.20K | 332.60K | 332.60K | 639.60K |
| Earnings from Continuing Operations | 2.19M | 2.19M | -6.55M | -6.55M | -2.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.19M | 2.19M | -6.55M | -6.55M | -2.93M |
| EBIT | -3.14M | -3.14M | -870.10K | -870.10K | -2.06M |
| EBITDA | -3.02M | -3.02M | -745.60K | -745.60K | -1.93M |
| EPS Basic | 100.50 | 100.50 | -- | -- | -- |
| Normalized Basic EPS | -91.78 | -91.78 | -- | -- | -- |
| EPS Diluted | 100.50 | 100.50 | -- | -- | -- |
| Normalized Diluted EPS | -91.78 | -91.78 | -- | -- | -- |
| Average Basic Shares Outstanding | 21.80K | 21.80K | -- | -- | -- |
| Average Diluted Shares Outstanding | 21.80K | 21.80K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |